New nonsteroidal eczema cream approved for kids

About this episode

The episode discusses the FDA approval of Tapinarof for treating eczema in children, featuring insights from Dr. Leon Kircik on its safety and efficacy.

New treatment alert!  The FDA recently approved Tapinarof, applied as a cream, for kids 2 years and up.  We ask Dr. Leon Kircik from Icahn School of Medicine, NY, who led the clinical trials about the safety, efficacy and side effects of Tapinarof.  And because we are parents too, we ask: How quickly does it work? Can you start/stop it as needed? How easy will it be to access? And more. If you like our podcast, please consider supporting it with a tax deductible donation . Research discussed Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children Maximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitis Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials Tapinarof cream in the treatment of atopic dermatitis in children and adults a systematic review and meta-analysis Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian…

People in this episode

Guest: Dr. Leon Kircik

Topics covered

• eczema treatment
• FDA approval
• pediatric dermatology
• Tapinarof
• atopic dermatitis
• clinical trials

Keywords

• eczema
• Tapinarof
• FDA approval
• children
• atopic dermatitis
• clinical trials
• dermatology

Mentioned in this episode

Organizations: Icahn School of Medicine

Products: Tapinarof

Books & works: Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children, Maximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitis, Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials, Efficacy and safety of Ruxolitinib, Crisaborole, and Tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs

More episodes of Eczema Breakthroughs

• New Eczema Treatments for Kids: Updates from the 2026 AAD Meeting and More · April 16, 2026 · 28 min
• Help your teen take charge of their eczema care—without turning it into a battle · February 19, 2026 · 27 min
• Eating fat-rich foods and changing baby skincare: Insights for prevention from GPER-funded research · January 26, 2026 · 30 min
• Will Removing Foods Help Your Child’s Eczema—or Make Things Worse? · November 5, 2025 · 22 min
• From Foe to Friend: Could common skin fungi be harnessed to heal the skin barrier? · October 15, 2025 · 19 min
• How to Choose & Use Products To Control Eczema: A Science-Backed Roadmap · August 28, 2025 · 38 min